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The physiology of vasopressin synthesis and secretion
Historical review Although the original anatomical description of the hypophysis cerebri was made by Galena there was relatively little advance in knowledge about the pituitary until the advent of light microscopy allowed Rathke to study its anatomical development.2 In 1859, Claude Bernard recognized that lesions in the corpus restiforme led to a nonglycosuric diuresis3 and subsequently the clinical association between basal skull fractures and polyuria provided the link between basilar structures of the brain and the regulation of urine volume.
The first advance in understanding the function of the posterior pituitary was the finding that posterior pituitary extracts exhibited vasopressor activity.4 The observation that intravenous injec-tions of posterior pituitary extracts in anaesthetized animals produced a temporary reduction in urine flow followed by a diureSiS5 led Frank to conclude that the primary fault in diabetes insipidus resided in the posterior pituitary gland which he attributed to the excess production of a diuretic principle. 6 6 Starling and Verney demonstrated an antidiuretic effect when an isolated canine kidney was perfused in the presence of a dog's head7 and Verney subsequently showed that removal of the pituitary gland caused failure of urine concentration. 8 These studies led to a correct interpretation of the role of the posterior pituitary in diabetes insipidus and to the use of posterior pituitary extracts in its treatment.9 9 _ Syntliesis and metabolism of vasopressin The pituitary gland is divided into the anterior lobe, the intermediate lobe and the posterior lobe (posterior pituitary). The gland is surrounded inferiorly and on all sides by the sella turcica (pituitary fossa) and is connected to the hypothalamus by the infundibular stalk. The dominant features of the neurohypophysis (hypothalamic-neural stalk-posterior pituitary unit) are the supra-opticohypophyseal and paraventriculohypophysheal nerve tracts. Originating from magnocellular neurones in the paraventricular and supra-optic nucleii within the hypothalamus, these tracts pass through the neural stalk to terminate as dilated endings on capillaries of the hypophyseal portal system within the posterior pituitary.
Vasopressin ( Two varieties of peripheral aVP receptors have been identified: the 'V1' receptor on smooth muscle and the 'V2' receptors in renal epithelia only the latter receptors activate adenylate cyclase.l3 V, receptor stimulation causes a rise in cytosolic Ca++ concentration via an increase in membrane phosphatidylinositol turnover, producing contraction in vascular smooth musclel4 and glycogenolysis in hepatocytes.ls Physiological control mechanisms for vasopressin secretion Maintenance of plasma osmolality is the major homeostatic function of the neurohypophysis. Under normal conditions of hydration the kidney is maximally stimulated to conserve water at plasma aVP concentrations of 1-Spg/m1.16 Plasma osmolality is normally set at approximately 282mOsm/kg and a rise to 287mOsm/kg initiates release of aVP which thereafter increases rapidly with rising osmolality. 17 Water loading suppresses aVP release. Decreases in blood volume or pressure both produce significant increases in circulating levels of plasma vasopressin. 17 Osmolality is the prime determinant of aVP release under nor-mal conditions, although during hypotension the osmotic set point is altered so that minor changes in osmolality cause increased secretion of aVP.
With severe loss of blood volume the osmotic control is overridden and massive increments in aVP may occur without marked changes in osmolality. ig Early experiments on water regulation in dogs indicated that emotional stress might increase aVP secretion, although Robertson has shown that this is not the caste. 17 Physical stress, however, is commonly associated with increased aVP secretion and this response appears to be independent of osmolality and volume control. Apomorphineinduced nausea causes increments of aVP of up to 500pg/ml17 and the area postrema in the wall of the fourth ventricle is thought to mediate this response. 19 Insulin-induced hypoglycaemia produces small increments of aVP of up to 8pg/ml, although the area in the brain responsible for this response is unknown. Baylis et al. concluded that this might be due to the effect of insulin,2o which has been shown to bind to the nucleus tractus solitarius and the area postrema.21 Major surgical procedures are associated with marked increments in plasma aVP concentrations which closely follow skin incision and bowel traction.22 This was thought to be mediated by pain rather than through volume receptors, as the response was abolished by cervical cordotomy but was unaffected by vagotomy. There is, however, evidence to suggest that pain does not stimulate aVP release,23 and other work has suggested that the response of aVP during operations is in fact mediated by volume and pressure receptors.24
Vasopressin and haemostasis
Physical stress such as occurs in response to surgery, hypoglycaemia, exercise and hypotension has been known for many years to cause changes in coagulation and fibrinolysis. The original observations linking hormones to these responses were made in the early part of this century and formed the basis of the idea that adrenergic mechanisms are responsible. 25,26 The major changes seen during stress are increases in factor VIII coagulation activity (FVIII:C), von Willebrand factor (VWF) and enhanced fibrinolytic activity.
In the circulation the factor VIII molecule exists as a complex of FVIII:C and VWF. FVIII:C acts as a cofactor in the intrinsic coagulation cascade and deficiency of this protein is the primary defect in classical haemophilia. VWF takes part in platelet-subendothelial binding and deficiency of VWF occurs in von Willebrand's disease.
The fibrinolytic system consists of activators and inhibitors which regulate the conversion of plasminogen to plasmin which acts to lyse fibrin. The principal activators of plasminogen are tissue plasminogen activator (t-PA) and urokinase (u-PA), whilst the most important inhibitor of t-PA and u-PA is PA inhibitor-1 (PAI-1).
In 1961, Schneck and von Kaulla showed that intravenous pitressin (a mixture of arginine and lysine vasopressin) caused an increase in plasminogen activator activity; they attributed this to the vasoconstrictive actions of aVP.27 Similar results were obtained with pharmacological doses of aVP,2g~29 but it was suggested that the increase in plasminogen activator could be a nonspecific response as it appeared to correlate with the severity of side effects, notably abdominal pain. The discovery that the synthetic analogue DDAVP produced increases in factor VIII:C, VWF:Ag and plasminogen activator,3o yet produced no abdominal pain and lacked vasoconstrictive effects suggested the existence of specific receptors for vasopressin on vascular endothelial cells. The effects of DDAVP on coagulation and fibrinolysis and its relative lack of side effects led to its clinical use and a rapid decline in interest in the parent molecule. The pharmacological effects of DDAVP have recently been reviewed. 31 Although it was thought that the levels of aVP required to affect coagulation and fibrinolysis were too high to be of any physiological significance, the development of sensitive radio-immunoassays for this peptide has led to studies which indicate that this may not be the case. Infusion of aVP into normal volunteers has shown that increases in fibrinolysis occur at plasma concentrations of about 15-20pg/m132 and in FVIII:C and VWF at 20-25pg/ml. 32, 33 The increase in fibrinolytic activity is due to a rise in t-PA rather than a fall in PAI-1. 34 Although the levels of aVP are not seen under normal circumstances, they are within the range that occurs during various forms of physical stress and the results support the idea that aVP may have a role in the regu-lation of coagulation and fibrinolysis in specific conditions.
Further studies of the relationship between aVP and changes in haemostasis have been hampered by the lack of availability of a specific aVP receptor blocker for use in man. However, during major abdominal surgery there were increases in aVP to median values of 51pg/ml immediately after bowel manipulation and this was temporally associated with increases both in FVIII:C and fibrinolytic activity35a similar relationship was observed during hip surgery. 36 The study of insulin-induced hypoglycaemia37 and apomorphine-induced nausea38 highlighted some of the problems in presuming that these temporal relationships indicated cause and effect. Similar changes in haemostasis occurred during hypoglycaemia, yet the increase in aVP was insufficient to have an effect. There was also a parallel increase in adrenaline concentrations during both hypoglycaemia and nausea which could have been responsible for the observed changes. In order to tease out the effects of aVP from those of adrenaline, two further studies were carried out in which adrenaline release did not occur. In a study of the effects of modified ECT there were increases in aVP levels associated with enhanced fibrinolytic activity, but no change in either adrenaline or FVIII concentrations. 39 These results suggest that aVP has only a minor role in the regulation of FVIII and that it is more important in fibrinolytic responses. Similar results were obtained in support of this view in the study of patients with rare forms of autonomic failure and their responses to postural hypotension.4~ There is no adrenaline or aVP release in response to hypotension in patients with Shy-Drager syndrome, whereas in Progressive Autonomic Failure (PAF) aVP is released normally and there is no adrenaline response. Results from this study, albeit in a small number of patients, showed that postural hypotension in Shy-Drager syndrome led to no change in adrenaline, aVP, FVIII or fibrinolysis, whereas in PAF the rise in aVP was associated with marked increases in fibrinolysis but no change in adrenaline or FVIII.
The mechanisms by which aVP exerts its effect on haemostasis remain unclear. It was initially considered that aVP caused an effect through its vasoactive properties, although the similar haemostatic effects of DDAVP argue against this view. Cash et al. and Prowse et al. have studied the structural requirements for the factor VIII and plasminogen activator responses to aVP. Using analogues of aVP they concluded that the whole molecule was required both for FVIII and plasminogen activator release and that the putative receptor could be differentiated from that on smooth muscle. On a molar basis aVP was found to be 80 times as potent as adrenaline for its effect on fibrinolytic responses. In addition, intraarterial infusion with venous sampling produced significant increases in plasminogen activator with adrenaline but had no effect with aVP. 41, 42 Adrenaline releases VWF:Ag from endothelial cell cultures,43 but aVP has not been shown to act directly to release either factor VIII:C or VWF:Ag.44 At present there is no evidence to suggest that the haemostatic effects of aVP are mediated by a direct effect on endothelial cells. It has been proposed that aVP might act by releasing a second messenger from the hypothalamus which acts directly on endothelial cells to produce changes in haemostasis. 44 Alternatively, aVP may act on one or more organs, such as the liver or kidney, distinct from vascular endothelial cells. It is also possible that aVP interacts in some way with catecholamines as there is a complex, partially understood relationship between autonomic function and aVP release. Although aVP does not increase catecholamine concentrations in peripheral blood,45 it is possible that an effect occurs either centrally or that adrenaline and aVP act synergistically.
Vasopressin and cardiovascular regulation ' Vasopressin was first identified by virtue of its pressor activity,4 although it is now apparent that there is a clear distinction between its pressor and vasoconstrictor effects.46 Whereas aVP may well have a physiological role in the control of regional blood flow47 and the distribution of cardiac output,48-50 it is unlikely, particularly in a normal man, to have any function in the long-term regulation of arterial blood pressure or in the maintenance of high blood pressure in human essential hypertension. 46 Vasopressin infusion induces a fall in heart rate and cardiac output in many species.51,52 Mechanisms are uncertain and, in common with direct effects on the microvasculature, may depend upon the species considered, the level of anaesthesia, the predominance of vagal or sympathetic tone and the dose or formulation of vasopressin used.46,47 The plasma levels of aVP required to increase arterial blood pressure are, however, very highslmany times greater than those found under basal conditions or with osmotic stimulation of vasopressin release. 53 Indeed, in man, infusion rates which increase plasma aVP by up to 500pg/ml have very little effect on mean arterial pressure, 46,54,55 whereas plasma levels below 20pg/ml -inducing no change in blood pressure -produce clear increases in total peripheral resistance48,51 and selective peripheral vasoconstriction.s6 Early studies suggested that aVP might, however, play a role in maintaining arterial pressure under certain extreme conditions: dogs with diabetes insipidus had an impaired blood pressure response to haemorrhage57; aVP appeared to play an important role in blood pressure regulation during haemorrhage in otherwise intact dogS58 and ratss9; plasma aVP response to a reduction in blood volume6~~61 was far greater than that required to cause maximum concentration of urine62; and arterial baroreceptors appeared to be involved in the control of vasopressin release.63 This and data gathered from studies involving hypophysectomy, replacement therapy with aVP and using pressor antagonists do, therefore, generally support the concept that aVP has an important role in maintaining vascular homeostasis after haemorrhage.
Similarly, hypovolaemia associated with dehydration induces rises in plasma aVP levels which seem to be associated with haemodynamic changes,64,65 although osmolality changes, rather than volume changes, appear to be the predominant determinant of aVP released. 17 Although aVP may be involved with short-term blood pressure control, its role in long-term blood pressure control is not established. Vasopressin has been implicated in some experimental models of hypertension,66 but has no clear role in human essential hypertension46; indeed, patients with raised circulating aVP levels associated with inappropriate secretion have blood pressure levels which are not significantly different from the normal populations. 67 Thus, although aVP may be involved under conditions of circulatory shock with the short-term maintenance of arterial blood pressure, its predominant haemodynamic role is likely to be in the control and the distribution of microcirculatory blood flow.
Mechanisms of cardiovascular control
Mechanisms by which aVP might influence cardiovascular function include direct Vi-receptormediated effects on vascular smooth muscle, modification of neurovascular control (either centrally or peripherally) and the baroreceptor reflex or by interaction with catecholamines and other vasoactive agents.
There is evidence from studies on isolated blood vessel preparations that aVP has a direct effect on vascular smooth muscle (largely constrictor, but also dilatator) in many mammalian vascular beds. 47 Liard,56 however, found that direct vasoconstrictor effects in the intact dog, at physiological plasma concentrations, appeared to be confined to vessels of the skin, pancreas and compact bone. In man, the potency of the direct vasoconstrictor effect of aVP has been demonstrated during intravenous infusion at therapeutic68 and subtherapeutic doses,69 findings which suggest that the vein wall is permeable to vasopressin which then induces constriction of local microvessels in the skin.
Sympathetic vasomotor pathways may be activated by local injection of vasopressin into the nucleus tractus solitarius and lateral cerebral ventricles, although vasopressin can also activate and augment parasympathetic pathways to the heart and baroreflex function when administered intravenously. 70 Furthermore, aVP-induced vasoconstriction is reduced by phenoxybenzamine, suggesting that part of the vasoconstrictor action of aVP depends upon the integrity of the sympathetic nervous system.50,71 It has been suggested that aVP may serve a compensatory role in maintaining haemodynamic homeostasis under conditions of impaired autonomic function. 72 Vasopressin would appear to be a physiological modulator of baroreflex function.46 Denervation of the baroreceptors causes a much greater increase in pressor responsiveness to aVP than to noradrenaline,52 leading to the suggestion that aVP can increase the gain of the baroreceptor reflex both in animals73,74 and in man. 75 This potentiation of the pressor response following total autonomic block may be due to prevention of a vagally-mediated decrease in cardiac output. 76 Vasopressin, in subpressor doses, can potentiate the pressor action of catecholamines on isolated mammalian aortic preparations,77 an effect attenuated by lithium, a V2 receptor antagonist, although lithium carbonate does not influence the vasoactivity of infused aVP in normal man. 78 In brain-dead patients, aVP has been shown to have a central role in circulatory stabilization, acting synergistically with catecholamines. 79 Our own preliminary studies suggest that there is no synergy between aVP and adrenaline in skin microvascular vasoactivity.80 Vasopressin infusion appears to induce a reduction in circulating noradrenaline.45 There seems to be little interaction between aVP and either angiotensin 1181 or atrial naturetic factor. 82
Vasopressin and the microcirculation
Krogh83 first demonstrated that the topical application of posterior pituitary extract produced constriction in the capillary bed of the webbed feet of frogs and the ears of dogs. It is now clear that aVP has a differential effect in various regions of the circulation, and interspecies responses are not congruous. 47, 84 Vasopressin in intact animals produces a proportionately greater reduction in blood flow to the skin, skeletal muscle, pancreas, thyroid gland and fat than the reduction in cardiac output.46 Blood flow is reduced proportionately to cardiac output in the myocardium, gastrointestinal tract and brain, whereas kidney and liver show no fall in blood flow. Changes in regional blood flow may also be demonstrated following endogenous aVP release, which decreases muscle,4g gastrointestinal and skin85 blood flow. Myocardial blood flow is unchanged and cerebral flow increased.
Arginine vasopressin is relatively selective in its effect within the microcirculation, inducing preferential constriction of muscular venules and, to a lesser extent, precapillary sphinc-tersg6 with less effect on arterioles and arteries.
Vasopressin potentiates the constrictor effect of catecholamines on precapillary vessels, whereas catecholamines alone have preferential action on arterioles and arteries. There is indirect evidence for similar selectivity within the skin circulation in man. 87 High physiological levels of aVP appear to induce constriction of venules and precapillary vessels, but facilitate increased arteriovenous shunting of blood.
Blood flow through the microvessels is subject to spontaneous rhythmic vasoconstrictions and dilatations. Vasopressin has been shown to induce or to greatly enhance such vasomotor activity, whereas angiotensin II, atrial naturetic factor and vasoactive intestinal polypeptide have no such effect. 88
Vasopressin and skin blood flow
The skin circulation in mammals functions to transport nutrients and metabolites, regulate body temperature, promote haemostasis and facilitate expression of emotion.
There have been few studies of the effects of physiological concentrations of aVP on skin and skeletal muscle blood flow in man. Conflicting results were obtained in early studies using relatively impure preparations at supraphysiological doses. Kunkel that vasodilatation was occurring in muscle blood vessels. More recently, aVP at high physiological levels in normal man has been shown to induce a reduction in hand skin nutritional blood flow, but to maintain high arteriovenous shunt flow in skin. 87 Thus, aVP, at physiological levels both in animals and man, has a direct effect on skin microvessels,46,~1 inducing vasoconstriction and increasing vasomotion. 88 The sympathetic vasoconstrictor system provides the predominant controlling mechanisms within the skin circulation. 92 Vasopressin may increase sympathetic tone when administered centrally,93-95 but has been shown to decrease sympathetic tone when administered systemically.72,96 Thus, interactions between aVP and the sympathetic nervous system are complex and would seem to involve more than one site72,97their interactions in controlling skin blood flow are unknown. Vasopressin and other vasoactive hormones could, however, play a part in regulating microvascular blood flow at times of complete or partial suppression of sympathetic vasomotor control, such as during insulin-induced hypoglycaemia.98
Temperature control
Vasopressin can produce a fall in body temperature in rats whether injected centrally99,lo0 or systemically. 101,102 The peripheral effect has been attributed to baroreflexive suppression of nonshivering thermogenesis and not to an effect on temperature regulation centres.lo2 It has also been suggested that aVP may have a role in maintaining homeostasis during fever. 103 The antidiuresis would alleviate the decrease in plasma volume whilst inducing changes in skin blood flow to dissipate heat. During insulin-induced hypoglycaemia, body temperature falls,lo4 a process facilitated by arteriovenous shunting of blood in skin despite a fall in capillary blood flow.9g This pattern of skin blood flow change is observed in man when aVP is infused intravenouslyg~ and during hypoglycaemia when skin blood flow varies proportionately to plasma aVP level. 98
Expression of emotion
Facial pallor has been described in man in states both of fear and rage. 105 Vasomotor control in facial skin differs from skin elsewhere because it is served by cholinergic fibres from the cervical sympathetic ganglial06 and by vasodilator fibres originating in the brain stem and leaving with the trigeminal nerves Circulating vasoactive agents may produce differential effects in facial skin blood flow compared to other regions. 108 The colour of the skin is determined by the capacitance vessels, i.e. the plexus of veins. Vasopressin has a predominant effect on muscular venules and induces facial pallor at physiological levels87; a similar degree of facial pallor has been observed in man during hypoglycaemia, a physical stress associated with vasopressin released. 87 Thus, at times of stress, vasopressin might be the circulating agent which induces facial pallor and expresses distress or emotion to observers.
Conclusion
The nonapeptide antidiuretic hormone, 8-arginine vasopressin, acts potently on the kidney to conserve water at low plasma concentrations. Plasma levels above those required for a maximal renal effect are commonly seen during various forms of physical stress and have been shown to modulate a number of physiological systems. Amongst these are changes in coagulation and fibrinolysis with vasoactive effects on the microcirculation. The significance of the changes in haemostasis remains unclear, although there is reason to believe that the acute increase in factor VIII may produce a tendency to a hypercoaguable state. The increase in systemic fibrinolytic activity may have a role in protecting the intact circulation from developing distant thrombosis in the event of local tissue injury. Further haemostatic regulation would be achieved by the generally vasoconstrictive effects of aVP in the skin microcirculation. The actions of higher levels of aVP may prepare the organism for the classic fight-or-flight response by redistributing cardiac output and activating the haemostatic systems. In this context, it is possible that whilst aVP acts as the antidiuretic hormone at low concentrations, at higher levels it could function as an 'antihaemorrhagic' hormone to maintain vascular integrity in the event of injury. 
